Source is pleased to announce it has listed three of its largest and most successful Exchange Traded Products (ETPs) on the Amsterdam section of the EURONEXT stock exchange. This should make it easier and cheaper for local investors to trade and settle the following products:
- The $3 billion Source S&P 500 UCITS ETF has an ongoing charge of just 0.05% per annum, making it one of the cheapest ways to get US equity exposure;
- The Source NASDAQ Biotech UCITS ETF is the only ETF in Europe that provides targeted exposure of the US biotechnology segment; and
- The Source Physical Gold ETC is the largest Source product, currently with more than US$ 3.4 billion of assets invested, backed by physical gold bullion.
“Investors who are looking for the most effective way to get exposure to a basic benchmark, such as the S&P 500, are increasingly turning to ETFs,” says Source’s Sjef Pieters, The Netherlands coverage. “They generally have low costs, trade throughout the day, and many often provide very accurate tracking of the index.”
Pieters continued: “Trump’s election victory triggered demand in these three areas of the market, with some investors thinking his growth plans will help US companies either broadly or in certain sectors such as biotech. At the same time, we have seen others wanting to add gold in case uncertainty or volatility escalates.”
The EURONEXT listings are the latest examples of Source’s commitment to bring high quality, fairly priced ETFs to investors across Europe. It follows a broad range of listings in Italy, which adds to those already in the UK, Switzerland and Germany.
EURONEXT listing summary
Source product name |
Bloomberg code |
Total cost p.a. |
Source S&P 500 UCITS ETF |
SPXS |
0.05% |
Source NASDAQ Biotech UCITS ETF |
SBIO |
0.40% |
Source Physical Gold ETC |
SGLD |
0.29% |